Ascendis Pharma A (ASND) Net Income towards Common Stockholders (2014 - 2026)

Ascendis Pharma A (ASND) has 13 years of Net Income towards Common Stockholders data on file, last reported at $740.4 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 843.24% year-over-year to $740.4 million; the trailing twelve-month figure through Mar 2026 stood at $582.0 million (up 541.36% YoY), and the FY2025 full-year result was -$269.6 million, up 34.13% from the prior year.
• Net Income towards Common Stockholders advanced to $740.4 million in Q1 2026, from -$39.6 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $740.4 million in Q1 2026 to a low of -$211.6 million in Q4 2022.
• A 5-year average of -$16.4 million and a median of -$87.6 million in 2022 frame the typical range for Net Income towards Common Stockholders.
• Across the five-year window, Net Income towards Common Stockholders slumped 282.13% in 2022 and jumped 843.24% in 2026, its largest moves.
• Tracing ASND's Net Income towards Common Stockholders over 5 years: stood at -$211.6 million in 2022, then jumped by 55.07% to -$95.1 million in 2023, then surged by 56.77% to -$41.1 million in 2024, then gained by 3.58% to -$39.6 million in 2025, then surged by 1967.84% to $740.4 million in 2026.
• Business Quant data shows ASND's Net Income towards Common Stockholders at $740.4 million in Q1 2026, -$39.6 million in Q4 2025, and -$73.1 million in Q3 2025.